NOVO HOLDINGS-BACKED REZERA FILES FOR A NASDAQ IPO
The clinical-stage company, which is developing oral NLRP3 inhibitors for cardiovascular and neurologic disease, plans to list under RZRA with Jefferies, TD Cowen and Cantor as joint bookrunners. Novo Holdings owned 24.42% and Blue Owl affiliates 24.03% before the IPO, per its SEC filing